Objective: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response.
Method: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to < 50% decrease for partial, ≥ 50% to < 75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment.
Results: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P = .017), moderate (23.1% vs 15.0%, P < .001), and robust response (14.3% vs 7.4%, P < .001) compared with adjunctive placebo. Adjunctive aripiprazole treatment compared with adjunctive placebo treatment was associated with a significantly greater proportion of patients achieving an early response (week 2, ≥ 50% reduction in MADRS total score, n = 110/539 vs n = 47/525, P < .001, number needed to treat = 9) and an endpoint response (relative risk = 1.7, 95% CI = 1.4-2.0, P < .001, number needed to treat = 7). A univariate logistic regression analysis revealed that an early response was a significant predictor of endpoint remission (P < .001).
Conclusions: Aripiprazole augmentation was associated with a significantly greater proportion of patients achieving a partial, moderate, or robust response to treatment compared with ADT alone. Patients showing an early response (week 2) to augmentation maintained their response through endpoint, suggesting that clinicians may make clinically meaningful decisions early during treatment.
Trial Registration: ClinicalTrials.gov identifiers: NCT00095823, NCT00095758, and NCT00105196.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466032 | PMC |
| http://dx.doi.org/10.4088/PCC.11m01251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cervical Cancer Screening in Women With Physical Disabilities.
JAMA Netw Open
January 2025
Department of Family Medicine, University of Michigan, Ann Arbor.
Importance: Cervical cancer screening is a crucial public health intervention, but screening disparities exist for women with physical disabilities (WWPD).
Objective: To explore the experiences of WWPD with both traditional speculum examination-based screening and at-home self-sampling for cervical cancer screening.
Design, Setting, And Participants: This qualitative study enrolled 56 WWPD to test self-sampling kits, provide feedback via a survey, and participate in a qualitative interview.
Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates.
Transl Vis Sci Technol
January 2025
STZ eyetrial at the Centre for Ophthalmology, Tuebingen, Germany.
Purpose: Reports of gene therapy-associated retinal atrophies and inflammation have highlighted the importance of preclinical safety assessments of adeno-associated virus (AAV) vector systems. We evaluated in nonhuman primates (NHPs) the ocular safety and toxicology of a novel AAV gene therapy targeting retinitis pigmentosa caused by mutations in PDE6A, which has since been used in a phase I/II clinical trial (NCT04611503).
Methods: A total of 34 healthy cynomolgus animals (Macaca fascicularis) were treated with subretinal injections of rAAV.
Hepatocyte Rho-associated kinase signaling is required for mice to survive experimental porphyria-associated liver injury.
Hepatol Commun
February 2025
Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
Background: Rho-associated kinases 1 and 2 (ROCK1 and ROCK2) regulate critical cell functions, including actomyosin contractility, apoptosis, and proliferation. Some studies suggest that ROCK inhibition may serve as a treatment for liver fibrosis. More investigation is needed to understand the role of hepatocyte ROCK signaling in vivo, especially in the context of profibrotic liver injury.
View Article and Find Full Text PDFDiagnostic Feasibility of Cardiac PET CT in the Evaluation of Inflammatory, Infectious, and Malignant Heart Disease.
R I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) is a power- ful imaging tool with diverse applications in the detection and diagnosis of various cardiac conditions, including inflammatory, infectious, and neoplastic processes. Using the radiotracer 18F-fluorodeoxyglucose (18F-FDG), cardiac PET enables the identification of cardiac involvement in diseases such as sarcoidosis and severe infections affecting the heart tissue. Additionally, 18F-FDG PET is valuable in the evaluation of cardiac masses, helping to assess their metabolic activity and potential malignancy.
View Article and Find Full Text PDFInflammation response post-radiofrequency ablation for atrial fibrillation: Implications for early atrial fibrillation recurrence.
Kardiol Pol
January 2025
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!